RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Hubei Minkang Pharmaceutical Stock

Hubei Minkang Pharmaceutical EBIT 2024

Hubei Minkang Pharmaceutical EBIT

41,950 USD

Ticker

HBMK

ISIN

US44352W1018

In 2024, Hubei Minkang Pharmaceutical's EBIT was 41,950 USD, a -95.9% increase from the 1.02 M USD EBIT recorded in the previous year.

The Hubei Minkang Pharmaceutical EBIT history

YEAREBIT (undefined USD)
20130.04
20121.02
20110.62
2010-0.07
2009-0.08
2008-0.12
2007-0.13
2006-0.08

Hubei Minkang Pharmaceutical Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Hubei Minkang Pharmaceutical, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Hubei Minkang Pharmaceutical from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Hubei Minkang Pharmaceutical’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Hubei Minkang Pharmaceutical. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Hubei Minkang Pharmaceutical’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Hubei Minkang Pharmaceutical’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Hubei Minkang Pharmaceutical’s growth potential.

Hubei Minkang Pharmaceutical Revenue, EBIT and net profit per share

DateHubei Minkang Pharmaceutical RevenueHubei Minkang Pharmaceutical EBITHubei Minkang Pharmaceutical Net Income
201314.74 M undefined41,950 undefined127,270 undefined
201213.92 M undefined1.02 M undefined961,120 undefined
201112.55 M undefined624,410 undefined-214,050 undefined
20100 undefined-67,130 undefined-768,820 undefined
20090 undefined-76,340 undefined-1.83 M undefined
20080 undefined-118,000 undefined-199,000 undefined
20070 undefined-130,000 undefined-130,000 undefined
20060 undefined-80,000 undefined-80,000 undefined

Hubei Minkang Pharmaceutical stock margins

The Hubei Minkang Pharmaceutical margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Hubei Minkang Pharmaceutical. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Hubei Minkang Pharmaceutical.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Hubei Minkang Pharmaceutical's sales revenue. A higher gross margin percentage indicates that the Hubei Minkang Pharmaceutical retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Hubei Minkang Pharmaceutical's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Hubei Minkang Pharmaceutical's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Hubei Minkang Pharmaceutical's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Hubei Minkang Pharmaceutical. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Hubei Minkang Pharmaceutical's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Hubei Minkang Pharmaceutical Margin History

Hubei Minkang Pharmaceutical Gross marginHubei Minkang Pharmaceutical Profit marginHubei Minkang Pharmaceutical EBIT marginHubei Minkang Pharmaceutical Profit margin
201342.66 %0.28 %0.86 %
201248.54 %7.36 %6.91 %
201147.83 %4.97 %-1.71 %
201042.66 %0 %0 %
200942.66 %0 %0 %
200842.66 %0 %0 %
200742.66 %0 %0 %
200642.66 %0 %0 %

Hubei Minkang Pharmaceutical Aktienanalyse

What does Hubei Minkang Pharmaceutical do?

Hubei Minkang Pharmaceutical Ltd is a Chinese pharmaceutical company that was founded in 1988. Since its establishment, the company has specialized in the development, production, and sale of medicines, particularly traditional Chinese medicines. The company is based in Xianning City, Hubei Province, and employs over 1,000 staff, including over 400 technicians and researchers. It is a leading manufacturer of medicines in China and has a good reputation in the national and international markets. Hubei Minkang Pharmaceutical has a wide business model that specializes in the development and marketing of medicines in various areas. These include: - Traditional Chinese Medicine: Traditional Chinese Medicine (TCM) is one of the company's specialties. TCM is a holistic approach that focuses on the body's natural healing powers. It involves the use of plants, minerals, and animal products to treat diseases and ailments. The company develops and produces a variety of TCM products that are highly valued by Chinese society. - State-of-the-Art Medicines: The company has also invested in modern medicines in recent years and has a specialized research and development department to develop these products. The portfolio also includes impressive developments in cancer therapy and treatment options for cardiovascular diseases. - Veterinary Medicine: Hubei Minkang Pharmaceutical Ltd also produces a wide range of products used in veterinary medicine. This includes remedies for parasites, antibiotics, and vitamins. - Research and Development: The company has established itself as an innovation driver through investment in the research and development of medicines. Hubei Minkang Pharmaceutical Ltd has been awarded with high-quality assurance and boasts a modern production facility that is standardized at the international level. The company has also received certifications from global institutions such as Good Manufacturing Practice (GMP). This ensures that all products are of the highest quality, safety, and efficacy. The company is committed to achieving its self-set corporate goals in a sustainable manner, thus creating a sense of shared responsibility towards the environment and society. Overall, Hubei Minkang Pharmaceutical Ltd is a company that focuses on the development, production, and sale of medicines, particularly traditional Chinese medicine. It has established itself as a successful player in the national and international markets through its specialized divisions and modern manufacturing processes. Hubei Minkang Pharmaceutical ist eines der beliebtesten Unternehmen auf Eulerpool.com.

EBIT Details

Analyzing Hubei Minkang Pharmaceutical's EBIT

Hubei Minkang Pharmaceutical's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Hubei Minkang Pharmaceutical's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Hubei Minkang Pharmaceutical's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Hubei Minkang Pharmaceutical’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Hubei Minkang Pharmaceutical stock

How much did Hubei Minkang Pharmaceutical achieve in EBIT for the current year?

In the current year, Hubei Minkang Pharmaceutical has achieved an EBIT of 41,950 USD.

What is EBIT?

EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company Hubei Minkang Pharmaceutical.

How has the EBIT of Hubei Minkang Pharmaceutical developed in recent years?

The EBIT of Hubei Minkang Pharmaceutical has increased by -95.905% decreased compared to the previous year.

What does EBIT mean for investors?

EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.

Why is EBIT an important indicator for investors?

Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.

Why do EBIT values fluctuate?

EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.

What role does tax burden play in EBIT?

Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.

How is EBIT presented in the balance sheet of the company Hubei Minkang Pharmaceutical?

The EBIT of Hubei Minkang Pharmaceutical is listed in the income statement.

Can EBIT be used as a single indicator for evaluating a company?

EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.

Why is EBIT not equal to net profit?

The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.

How much dividend does Hubei Minkang Pharmaceutical pay?

Over the past 12 months, Hubei Minkang Pharmaceutical paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Hubei Minkang Pharmaceutical is expected to pay a dividend of 0 USD.

What is the dividend yield of Hubei Minkang Pharmaceutical?

The current dividend yield of Hubei Minkang Pharmaceutical is .

When does Hubei Minkang Pharmaceutical pay dividends?

Hubei Minkang Pharmaceutical pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Hubei Minkang Pharmaceutical?

Hubei Minkang Pharmaceutical paid dividends every year for the past 0 years.

What is the dividend of Hubei Minkang Pharmaceutical?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Hubei Minkang Pharmaceutical located?

Hubei Minkang Pharmaceutical is assigned to the 'Health' sector.

Wann musste ich die Aktien von Hubei Minkang Pharmaceutical kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Hubei Minkang Pharmaceutical from 10/3/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/3/2024.

When did Hubei Minkang Pharmaceutical pay the last dividend?

The last dividend was paid out on 10/3/2024.

What was the dividend of Hubei Minkang Pharmaceutical in the year 2023?

In the year 2023, Hubei Minkang Pharmaceutical distributed 0 USD as dividends.

In which currency does Hubei Minkang Pharmaceutical pay out the dividend?

The dividends of Hubei Minkang Pharmaceutical are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Hubei Minkang Pharmaceutical

Our stock analysis for Hubei Minkang Pharmaceutical Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Hubei Minkang Pharmaceutical Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.